GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEF

Design
Animal study
Drugs
Tirzepatide
Assessment
Facts extracted automatically · reviewed by Carrie Schluter, Nov 5, 2026 · added Oct 18, 2026

This study was added automatically, and its details were extracted by machine rather than read off the paper by a person. Carrie Schluter has reviewed the record, but that review did not re-extract those details, so the collection still publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.

01Source

The source, as retrieved

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a complex, multi-organ cardiometabolic syndrome lacking universally effective therapies. We developed and validated a robust murine model leveraging complete, constitutive genetic endothelial nitric oxide synthase deficiency (eNOS KO) coupled with metabolic stress via a high-fat diet (HFD) in both male and female cohorts. eNOS KO mice subjected to HFD (10 weeks for males; 15 weeks for females) developed a severe and highly reproducible cardiometabolic HFpEF phenotype. Despite preserved left ventricular ejection fraction, both sexes exhibited profound diastolic dysfunction, characterized by elevated E/e' ratios and left ventricular end-diastolic pressures (LVEDP), alongside severe exercise intolerance. Consistent with the systemic clinical syndrome, pathological remodeling extended to multi-organ damage, featuring prominent cardiac fibrosis, severe hepatic steatosis, and renal tubulointerstitial fibrosis. Finally, chronic administration of the dual GIP/GLP-1 receptor agonist tirzepatide largely reversed the hemodynamic, functional, and systemic fibrotic derangements. In conclusion, this novel eNOS KO mouse + HFD model provides a rapidly developing, highly penetrant, and chemically unconfounded platform that ensures robust HFpEF induction across both sexes. This model can be readily adopted for the investigation of mechanistic insights into HFpEF pathobiology and for the study of novel HFpEF therapeutics.

Where this record came from

SourceRetrievedIdentifier
pubmedSep 20, 202642743759
first ingestion
pubmedSep 20, 202642743759
duplicate matched on doi
pubmedSep 20, 202642743759
duplicate matched on doi
pubmedSep 27, 202642743759
duplicate matched on doi
pubmedSep 27, 202642743759
duplicate matched on doi
pubmedSep 27, 202642743759
duplicate matched on doi
owner-reviewNov 6, 2026
reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision.